I agree that this site is using cookies. You can find further informations here.
X
Heaney, Mark L.
361  results:
Search for persons X
?
1

Anagrelide for platelet-directed cytoreduction in polycythe..:

Rippel, Noa ; Tremblay, Douglas ; Zubizarreta, Nicole...
Leukemia Research.  119 (2022)  - p. 106903 , 2022
Link: https://doi.org/10.1016/..
 
?
2

European LeukemiaNet Response Predicts Disease Progression ..:

Tremblay, Douglas ; Srisuwananukorn, Andrew ; Ronner, Lukas...
HemaSphere.  6 (2022)  6 - p. e721 , 2022
Link: https://doi.org/10.1097/..
 
?
3

Efficacy and safety of avapritinib in advanced systemic mas..:

Gotlib, Jason ; Reiter, Andreas ; Radia, Deepti H....
Nature Medicine.  27 (2021)  12 - p. 2192-2199 , 2021
Link: https://doi.org/10.1038/..
 
?
4

Ruxolitinib discontinuation in polycythemia vera: Patient c..:

Tremblay, Douglas ; Ronner, Lukas ; Podoltsev, Nikolai...
Leukemia Research.  109 (2021)  - p. 106629 , 2021
Link: https://doi.org/10.1016/..
 
?
5

PIONEER: A Randomized, Double-Blind, Placebo-Controlled, Ph..:

Akin, Cem ; Elberink, Hanneke Oude ; Gotlib, Jason...
Journal of Allergy and Clinical Immunology.  145 (2020)  2 - p. AB336 , 2020
Link: https://doi.org/10.1016/..
 
?
6

ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion ..:

Oh, Stephen T. ; Talpaz, Moshe ; Gerds, Aaron T....
Blood Advances.  4 (2020)  18 - p. 4282-4291 , 2020
Link: https://doi.org/10.1182/..
 
?
7

Phase 2 study of ruxolitinib and decitabine in patients wit..:

Mascarenhas, John O. ; Rampal, Raajit K. ; Kosiorek, Heidi E....
Blood Advances.  4 (2020)  20 - p. 5246-5256 , 2020
Link: https://doi.org/10.1182/..
 
?
8

Corrigendum to "Phase 1/2 trial of glasdegib in patients wi..:

Gerds, Aaron T. ; Tauchi, Tetsuzo ; Ritchie, Ellen...
Leukemia Research.  81 (2019)  - p. 105 , 2019
Link: https://doi.org/10.1016/..
 
?
9

Phase 1/2 trial of glasdegib in patients with primary or se..:

Gerds, Aaron T. ; Tauchi, Tetsuzo ; Ritchie, Ellen...
Leukemia Research.  79 (2019)  - p. 38-44 , 2019
Link: https://doi.org/10.1016/..
 
?
10

Clonal diversity predicts adverse outcome in chronic lympho..:

Leeksma, Alexander C. ; Taylor, Justin ; Wu, Bian...
Leukemia.  33 (2018)  2 - p. 390-402 , 2018
Link: https://doi.org/10.1038/..
 
?
11

Safety and efficacy of combined ruxolitinib and decitabine ..:

Rampal, Raajit K. ; Mascarenhas, John O. ; Kosiorek, Heidi E....
Blood Advances.  2 (2018)  24 - p. 3572-3580 , 2018
Link: https://doi.org/10.1182/..
 
?
12

A Phase I Trial of a Pharmacodynamically-Conceived Thioguan..:

Lee, Daniel ; Rosenblat, Todd ; Heaney, Mark...
Clinical Lymphoma Myeloma and Leukemia.  16 (2016)  - p. S24 , 2016
Link: https://doi.org/10.1016/..
 
?
13

A phase IIa study of afuresertib, an oral pan‐AKT inhibitor..:

Arceci, Robert J. ; Allen, Carl E. ; Dunkel, Ira J....
Pediatric Blood & Cancer.  64 (2016)  5 - p. , 2016
Link: https://doi.org/10.1002/..
 
?
14

Zeroing in on cereblon:

Heaney, Mark L.
European Journal of Haematology.  95 (2015)  1 - p. 1-2 , 2015
Link: https://doi.org/10.1111/..
 
?
15

Treatment Outcomes in CML Patients Treated With Tyrosine Ki..:

Sissolak, Gerhard ; Badenhorst, Jacques ; Steenkamp, Janami...
Clinical Lymphoma Myeloma and Leukemia.  15 (2015)  12 - p. 803-810 , 2015
Link: https://doi.org/10.1016/..
 
1-15